Emerging drug delivery devices, such as BBB-penetrating nanoparticles specifically designed for delivering drug combinations [66,67] or focused ultrasound-enhanced delivery [68] to optimize delivery of FAK+MEK inhibitor combinations to GBM tumors, can be considered. This evidence concerns the gene PTK2 and glioblastoma.